Abstract
The role of redox regulation in immune-mediated arthritis has been previously described. However, the relationship between innate immune cells, including innate lymphoid cells (ILCs) and phagocyte-derived ROS, in this process remains unclear. Here, we characterize ILCs and measure the IL-1 family cytokines along with other cytokines relevant to ILC functions and development in serum-induced arthritic joints in wild type and phagocytic NADPH oxidase (NOX2)-deficient Ncf1-/- mice. We found more severe serum-induced joint inflammation and increased NCR+ ILC3s in inflamed joints of Ncf1-/- mice. Furthermore, in vitro stimulation with IL-1β on Tbet+ ILC1s from joints facilitated their differentiation into ROR-γt+ ILC3s. Moreover, treatment with IL-1 antagonists effectively lowered the proportions of NCR+ ILC3s and IL-17A producing ILC3s in Ncf1-/- arthritic mice and ameliorated the joint inflammation. These results suggest that NOX2 is an essential regulator of ILC transdifferentiation and may mediate this process in a redox-dependent manner through IL-1β production in the inflammatory joint. Our findings shed important light on the role of ILCs in the initiation and progression in tissue inflammation and delineate a novel innate immune cell-mediated pathogenic mechanism through which redox regulation may determine the direction of immune responses in joints.
Keywords:
NADPH oxidase; chronic granulomatous disease; innate lymphoid cells; reactive oxygen species; serum-induced arthritis.
© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Antirheumatic Agents / pharmacology
-
Arthritis, Experimental / chemically induced
-
Arthritis, Experimental / drug therapy
-
Arthritis, Experimental / immunology
-
Arthritis, Experimental / pathology
-
Gene Expression Regulation / immunology
-
Immunity, Innate / drug effects
-
Interleukin 1 Receptor Antagonist Protein / pharmacology
-
Interleukin-17 / genetics
-
Interleukin-17 / immunology
-
Interleukin-1beta / genetics
-
Interleukin-1beta / immunology*
-
Lymphocytes / drug effects
-
Lymphocytes / immunology*
-
Lymphocytes / pathology
-
Male
-
Mice
-
Mice, Inbred C57BL
-
Mice, Knockout
-
NADPH Oxidase 2 / deficiency*
-
NADPH Oxidase 2 / genetics
-
NADPH Oxidase 2 / immunology
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / genetics
-
Nuclear Receptor Subfamily 1, Group F, Member 3 / immunology
-
Oxidation-Reduction / drug effects
-
Phagocytes / drug effects
-
Phagocytes / immunology
-
Phagocytes / pathology
-
Reactive Oxygen Species / antagonists & inhibitors
-
Reactive Oxygen Species / immunology*
-
Serum / immunology
-
Signal Transduction
-
T-Box Domain Proteins / genetics
-
T-Box Domain Proteins / immunology
-
Tarsus, Animal / drug effects
-
Tarsus, Animal / immunology*
-
Tarsus, Animal / pathology
Substances
-
Antirheumatic Agents
-
IL1B protein, mouse
-
Il17a protein, mouse
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-17
-
Interleukin-1beta
-
Nuclear Receptor Subfamily 1, Group F, Member 3
-
Reactive Oxygen Species
-
Rorc protein, mouse
-
T-Box Domain Proteins
-
T-box transcription factor TBX21
-
Cybb protein, mouse
-
NADPH Oxidase 2